Bridge Biotherapeutics Financials
| 288330 Stock | KRW 3,940 120.00 2.96% |
Bridge |
Understanding current and past Bridge Biotherapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bridge Biotherapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Bridge Biotherapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Bridge Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bridge Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bridge Biotherapeutics' management manipulating its earnings.
Bridge Biotherapeutics Stock Summary
Bridge Biotherapeutics competes with KNOTUS CoLtd, AptaBio Therapeutics, Cytogen, and Genolution. Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea.| Instrument | Korea Stock View All |
| Exchange | KOSDAQ |
| Business Address | Building B, Innovalley, |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Benchmark | Dow Jones Industrial |
| Website | bridgebiorx.com |
| Currency | KRW - South Korean Won |
You should never invest in Bridge Biotherapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bridge Stock, because this is throwing your money away. Analyzing the key information contained in Bridge Biotherapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Bridge Biotherapeutics Key Financial Ratios
Bridge Biotherapeutics' financial ratios allow both analysts and investors to convert raw data from Bridge Biotherapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Bridge Biotherapeutics over time and compare it to other companies across industries.Bridge Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bridge Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Bridge Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bridge Biotherapeutics competition to find correlations between indicators driving Bridge Biotherapeutics's intrinsic value. More Info.Bridge Biotherapeutics is rated below average in return on equity category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bridge Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bridge Biotherapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bridge Biotherapeutics Systematic Risk
Bridge Biotherapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bridge Biotherapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Bridge Biotherapeutics correlated with the market. If Beta is less than 0 Bridge Biotherapeutics generally moves in the opposite direction as compared to the market. If Bridge Biotherapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bridge Biotherapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bridge Biotherapeutics is generally in the same direction as the market. If Beta > 1 Bridge Biotherapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Bridge Biotherapeutics December 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bridge Biotherapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bridge Biotherapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bridge Biotherapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Bridge Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bridge Biotherapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 6.03 | |||
| Information Ratio | 0.0287 | |||
| Maximum Drawdown | 41.45 | |||
| Value At Risk | (9.94) | |||
| Potential Upside | 14.21 |
Complementary Tools for Bridge Stock analysis
When running Bridge Biotherapeutics' price analysis, check to measure Bridge Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bridge Biotherapeutics is operating at the current time. Most of Bridge Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bridge Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bridge Biotherapeutics' price. Additionally, you may evaluate how the addition of Bridge Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |